Table 2.
Multivariate analysis of immune response-related and proliferation markers for disease- free survival and overall survival.
| Variables | DFS | OS | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| pCR | 0.01 | 0.01 – 0.78 | 0.042 | 0.04 | 0.01 – 1.61 | 0.090 |
| HR+ | 0.23 | 0.04 – 1.16 | 0.075 | 0.14 | 0.03 – 0.81 | 0.027 |
| HER2+ | 0.15 | 0.14 – 1.74 | 0.131 | 0.25 | 0.03 – 2.10 | 0.204 |
| NLR | 1.80 | 1.12 – 2.88 | 0.014 | 1.37 | 1.03 – 1.83 | 0.033 |
| TILs* | 0.93 | 0.83 – 1.05 | 0.259 | 0.86 | 0.75 – 0.98 | 0.026 |
| AURKA* | 1.04 | 1.00 – 1.08 | 0.069 | 1.04 | 1.00 – 1.09 | 0.090 |
| MYBL2* | 1.13 | 1.01 – 1.27 | 0.037 | 1.19 | 1.05 – 1.35 | 0.007 |
AURKA, Aurora kinase A; DFS, disease-free survival; HER2+, human epidermal growth factor receptor 2 positive; HR, hazard ratio; HR+, hormone receptors positive; MYBL2, MYB Proto-Oncogene Like 2; NLR, neutrophil-to-lymphocyte ratio; OS, overall survival; pCR, pathological complete response; TILs, tumor-infiltrating lymphocytes; 95% CI, 95% confidence interval.
*Square root transformation of these variables was performed.